As I understand it in terms of the PRV voucher HIE will not be the first indication for which ARG 007 is approved.
Argenica is targeting stroke first which is a significantly larger market. So I presume Argenica will not be eligible for the Voucher. Hopefully Argenica can advance studies on the HIE application in a timely manner for this unmet need which is currently grant funded. I don't think future funding of HIE, TBI and Alzheimers will be an issue when it looks like the stroke application looks like a goer.
$100M Market Cap, page-18
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
90.0¢ |
Change
-0.030(3.23%) |
Mkt cap ! $111.3M | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.0¢ | 88.0¢ | $298.2K | 331.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 88.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.0¢ | 14400 | 3 |
View Market Depth
| Last trade - 15.59pm 12/07/2024 (20 minute delay) ? |
| AGN (ASX) Chart |